IRRI study highlights targeted investment in direct-seeded rice to enhance climate resilience and sustainability in Indian ...

ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for ...

ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease ...

Dr. Sumit Sharma, retina and uveitis specialist at the Cole Eye Institute, will present first-time end-of-study clinical results, including Week 24 data, from the Phase 1b APEX study in patients with ...

All-stock transaction brings Tempest a portfolio of next-generation CAR-T assets, including TPST-2003, a clinical-stage ...

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational ...

Axon Neuroscience’s active tau immunotherapy, AADvac1, has been selected as the first tau-targeted therapy to enter a ...

Zura Bio Limited ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and ...

Plants are a rich and renewable source of compounds used in medicines, food ingredients, and cosmetics. Since growing an ...

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today provided an update on its ongoing collaboration with Syntekabio, Inc., an ...

A new study led by the University of Miami Miller School of Medicine's Kirill Martemyanov, Ph.D., and international collaborators highlights a new approach to treating depression that bypasses many ...

Two U.S. senators this week introduced a bill that would create new rules around the sale of synthetic gene sequences that could be used to create bioweapons. Synthetic ‍genes are sequences of nucleic ...